My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking
Reliance Capital gains after board approves independent listing of home finance business

Reliance Capital gains after board approves independent listing of home finance business

Sep 14,2016

The announcement was made yesterday, 13 September 2016, when stock market remained closed on account of Bakri Id.

Meanwhile, the S&P BSE Sensex was down 46.19 points or 0.16% at 28,307.35.

On BSE, so far 6.75 lakh shares were traded in the counter as against average daily volume of 5.01 lakh shares in the past one quarter. The stock hit a high of Rs 561.50 and a low of Rs 546.65 so far during the day. The stock had hit a 52-week high of Rs 574 on 9 September 2016. The stock had hit a 52-week low of Rs 303.60 on 12 February 2016. The stock had outperformed the market over the past one month till 12 September 2016, rising 21.96% compared with 0.71% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 32.06% as against Sensexs 6.45% rise.

The large-cap company has equity capital of Rs 252.63 crore. Face value per share is Rs 10.

Reliance Capital said the independent listing of Reliance Home Finance (RHF) is expected to unlock substantial value for existing shareholders of Reliance Capital. The listing of Reliance Home Finance will also lead to increased management focus and accelerated growth in the home finance business. As per the proposal, 49% stake in Reliance Home Finance Limited will be allotted to all shareholders of Reliance Capital, in the ratio of one share free of cost in Reliance Home Finance for every one share held in Reliance Capital.

Reliance Capital will hold a 51% stake in Reliance Home Finance, and the company will be adequately capitalised to grow the lending book to over Rs 20000 crore in the next 18 months. The proposal is subject to necessary shareholders and other approvals. Reliance Home Finance, a 100% subsidiary of Reliance Capital, provides a wide range of loan solutions like home loan, LAP, construction finance and affordable housing loans. The company reported an AUM of Rs 8259 crore ($1.2 billion) during the quarter ended 30 June 2016.

Mr. Anmol A. Ambani, Director, Reliance Capital said Prime Minister, Narendra Modi has set a goal of affordable housing for all by 2022. There is presently an estimated shortage of 10 crore residential units in India. To address the needs of this sector, Reliance Home Finance has charted an aggressive growth plan in this space, and aims to increase its book size to over Rs 50000 crore in the next few years.

On a consolidated basis, Reliance Capitals net profit rose 3% to Rs 207 crore on 48.3% growth in total income to Rs 3663 crore in Q1 June 2016 over Q1 June 2015.

Reliance Capital, a part of the Reliance Group, is one of Indias leading private sector financial services companies.

Powered by Capital Market - Live News

V-Mart Retail attracts buyers after opening new store
Mar 29,2017

The announcement was made during market hours today, 29 March 2017.

Meanwhile, the S&P BSE Sensex was up 69.05 points or 0.23% at 29,478.57. The S&P BSE Small-Cap index was up 30.05 points or 0.21% to 14,183.42.

More than usual volumes were witnessed on the counter. On the BSE, 61,653 shares were traded on the counter so far as against the average daily volumes of 29,745 shares in the past one quarter. The stock had hit a high of Rs 847.30 and a low of Rs 788 so far during the day. The stock had hit a record high of Rs 883.75 on 9 March 2017. The stock had hit a 52-week low of Rs 425 on 24 June 2016.

The small-cap company has equity capital of Rs 18.07 crore. Face value per share is Rs 10.

V-Mart Retail said that the store is a fashion store. With the opening of the store, the tally of stores in Bihar is 5 composite & 26 fashion stores. This takes the total number of stores to 141 stores in 121 cities across 14 states, with 37 composite stores & 104 fashion stores with a total area of around 11.95 lakhs square feet.

V-Mart Retail net profit rose 81.3% to Rs 27.21 crore on 23.2% growth in net sales to Rs 326.49 crore in Q3 December 2016 over Q3 December 2015.

V-Mart Retail is a hypermarket format retail chain based in New Delhi. It is a multi-brand family retail store offering apparels, general merchandise and kirana.

Powered by Capital Market - Live News

Panacea Biotec launches EasySix vaccine
Mar 29,2017

Panacea Biotec announced the launch of Worlds first fully liquid whole cell Pertussis (wP) based Hexavalent Combination Vaccine, EasySix, a vaccine researched, development and manufactured by Panacea Biotec in India.

EasySix is indicated for primary immunization to protect newborn babies against six common preventable diseases viz, Diphtheria, Tetanus, Whooping Cough, Meningitis (due to H. Influenza type b), Hepatitus B and Polio.

Powered by Capital Market - Live News

Panacea Biotec in pink of health after launching vaccine
Mar 29,2017

The announcement was made during market hours today, 29 March 2017.

Meanwhile, the S&P BSE Sensex was up 105.96 points, or 0.36% to 29,515.48. The S&P BSE Small-Cap index was up 60.44 points or 0.43% to 14,213.81.

On the BSE, 39,933 shares were traded in the counter so far, compared with average daily volumes of 47,302 shares in the past one quarter. The stock had hit a high of Rs 167.80 and a low of Rs 153.05 so far during the day. The stock had hit a 52-week high of Rs 178.30 on 27 January 2017. The stock had hit a 52-week low of Rs 85.50 on 26 May 2016.

The small-cap company has equity capital of Rs 6.13 crore. Face value per share is Re 1.

Panacea Biotec said the vaccine was researched, developed and manufactured by the company in India. EasySix is indicated for primary immunization to protect newborn babies against six preventive diseases namely, Diptheria, Tetanus, Whopping Cough, Hepatitis B and Polio.

Panacea Biotec reported net loss of Rs 29.25 crore in Q3 December 2016, higher than net loss of Rs 17.38 crore in Q3 December 2015. Net sales declined 34% to Rs 99.33 crore in Q3 December 2016 over Q3 December 2015.

Panacea Biotec is one of Indias leading research based biotechnology companies with established research, manufacturing and marketing capabilities.

Powered by Capital Market - Live News

Siemens and Sumitomo Electric Industries consortium wins order from PGCIL
Mar 29,2017

A consortium of Siemens and Sumitomo Electric Industries has been awarded an order from Power Grid Corporation of India, the central transmission utility of India, to supply a high-voltage direct current (HVDC) transmission system. The total size of the order won by the consortium is US $520 million, of which the share of Siemens is approximately Rs 1,682 crore.

Powered by Capital Market - Live News

Board of CHD Chemicals allots equity shares on conversion of warrants
Mar 29,2017

CHD Chemicals announced that the Board of Directors of the Company at its meeting held on 29 March 2017 has made the allotment of 12.45 lakh equity shares at an issue price of Rs 10 each on conversion of warrants. With this allotment, the paid up equity share capital has increased to Rs 6.45 crore comprising of 6454080 equity shares of Rs 10 each.

Powered by Capital Market - Live News

Talwalkars Better Value Fitness provides business update
Mar 29,2017

Talwalkars Better Value Fitness announced the opening of 10 Zorba - Renaissance studios.

Powered by Capital Market - Live News

Dishman Pharmaceuticals & Chemicals leads gainers in A group
Mar 29,2017

Dishman Pharmaceuticals & Chemicals jumped 10.17% at Rs 306.50 at 13:45 IST with the stock extending Tuesdays rally amid media reports surrounding US drug regulators approval for a cancer drug.. The stock topped the gainers in the BSEs A group. On the BSE, 21.83 lakh shares were traded on the counter so far as against the average daily volumes of 1.7 lakh shares in the past two weeks. Dish Pharma clarified that since it does not manufacture the innovators end product in contract research and manufacturing services (CRAMS) segment, it is Tesaro Inc., which has received the USFDA approval for cancer drug Zejula Capsules and not Dishman Pharma as mentioned in media reports.

Edelweiss Financial Services jumped 6.54% at Rs 155.55. The stock was the second biggest gainer in A group. On the BSE, 16.57 lakh shares were traded on the counter so far as against the average daily volumes of 47.37 lakh shares in the past two weeks.

Cox & Kings gained 6.22% to Rs 221.90. The stock was the third biggest gainer in A group. On the BSE, 5.03 lakh shares were traded on the counter so far as against the average daily volumes of 45,000 shares in the past two weeks.

Shipping Corporation of India rose 6.14% at Rs 73.50. The stock was the fourth biggest gainer in A group. On the BSE, 8.8 lakh shares were traded on the counter so far as against the average daily volumes of 9.94 lakh shares in the past two weeks.

Muthoot Finance rose 5.13% to Rs 369. The stock was the fifth biggest gainer in A group. On the BSE, 1 lakh shares were traded on the counter so far as against the average daily volumes of 25,000 shares in the past two weeks.

Powered by Capital Market - Live News

Power Grid Corporation of India to establish transmission system in Eastern Region
Mar 29,2017

Power Grid Corporation of India has on 28 March 2017 acquired Medinipur-Jeerat Transmission, the project SPV to establish transmission system for 765kV strengthening in Eastern Region (ERSS-XVIII) on build, own, operate and maintain basis from PFC Consulting. The transmission system includes establishment of 765kV and 400kV transmission lines including establishment of two new 765/400kV substations. The transmission system is to be progressively constructed over a period of 40 months.

Powered by Capital Market - Live News

Tata Metaliks announces cessation of director
Mar 29,2017

Tata Metaliks announced that Ashok K Basu has retired as Independent Director on the Board of the Company on 23 March 2017.

Powered by Capital Market - Live News

UCO Bank nudges higher on capital raising plans
Mar 29,2017

The issue is a private placement of unsecured redeemable non-convertible fully paid up Basel III compliant tier II bonds in the nature of debentures.

The announcement was made during market hours today, 29 March 2017.

Meanwhile, the S&P BSE Sensex was up 88.02 points, or 0.3% to 29,497.54. The S&P BSE Mid-Cap index was up 39.80 points or 0.29% to 13,951.45.

On the BSE, 76,475 shares were traded in the counter so far, compared with average daily volumes of 1.44 lakh shares in the past one quarter. The stock had hit a high of Rs 36.80 and a low of Rs 36.20 so far during the day. The stock had hit a 52-week high of Rs 46.60 on 15 July 2016. The stock had hit a 52-week low of Rs 29.50 on 9 November 2016.

The mid-cap company has equity capital of Rs 1559.73 crore. Face value per share is Rs 10.

UCO Bank reported net loss of Rs 437.09 crore in Q3 December 2016 as against net loss of Rs 1497.01 crore in Q3 December 2015. Operating income declined 1.4% to Rs 4864.21 crore in Q3 December 2016 over Q3 December 2015.

The Government of India held 76.67% stake in UCO Bank as on 31 December 2016 as per the shareholding pattern.

Powered by Capital Market - Live News

Kalpataru Power Transmission secures new orders
Mar 29,2017

Kalpataru Power Transmission has secured new orders worth Rs 1200 crore.

Powered by Capital Market - Live News

IndusInd Bank partners with Lohia Auto Industries
Mar 29,2017

Lohia Auto Industries announced that IndusInd Bank would be its preferred financier for financing their electric three wheelers under the e-rickshaw category. This is in addition to the financing of diesel vehicles which the bank already provides. Through this partnership IndusInd Bank will offer retail vehicle finance at attractive rates of interest to the customers of Lohia Auto, for all Lohia 3-wheeler electronic and diesel models. This partnership will simplify the process for customers to take up three-wheeler by providing loans which are hassle free and competitively priced.

Powered by Capital Market - Live News

Board of Poly Medicure allots 4,41,13,440 bonus shares
Mar 29,2017

Poly Medicure announced that the Allotment committee of the Board of Directors of the Company, at its meeting held on 29 March 2017 has approved allotment of 4,41,13,440 fully paid Bonus Equity Shares of Rs. 5 each (Rs. Five) in the ratio of 1:1 (i.e. 1 (One) new equity bonus shares of Rs. 5 each for every 1 (one) existing fully paid equity share of Rs. 5 each held) to the members holding shares as on the Record Date i.e. 28 March 2017.

Powered by Capital Market - Live News

Loyal Equipments receives order worth Rs 1.01 crore
Mar 29,2017

Loyal Equipments has received an order worth Rs 1.01 crore from Engineers India for Ramagundam Fertilisers & Chemicals for supply of KO Drum & Inter Stage Separator.

Powered by Capital Market - Live News

Dishman Pharma extends Tuesdays sharp rally
Mar 29,2017

Meanwhile, the S&P Sensex was up 98.74 points or 0.34% at 29,508.26. The S&P BSE Mid-cap index was up 40.15 points or 0.29% at 13,951.80.

High volumes were witnessed on the counter. On the BSE, 20.19 lakh shares were traded on the counter so far as against the average daily volumes of 2.01 lakh shares in the past one quarter. The stock had hit a high of Rs 321.50 so far during the day, which is also its record high. The stock hit a low of Rs 287.95 so far during the day.

The stock had hit a 52-week low of Rs 127.60 on 24 June 2016. It had outperformed the market over the past one month till 28 March 2017, advancing 20.59% compared with the Sensexs 2.32% rise. The scrip had also outperformed the market over the past one quarter advancing 32.67% as against the Sensexs 12.2% rise.

The mid-cap company has equity capital of Rs 32.28 crore. Face value per share is Rs 2.

Shares of Dishman Pharmaceuticals & Chemicals (Dishman Pharma) have rallied 32.41% in two trading sessions from Rs 231.85 on 27 March 2017. The stock had rallied 20% to settle at Rs 278.20 yesterday, 28 March 2017 on media reports that the company has received approval from the US Food and Drug Administration (USFDA) for cancer drug Zejula Capsules.

Dish Pharma, in a clarification issued to the stock exchanges during market hours yesterday, 28 March 2017, said that the company is bound by strict confidentiality agreements with its customers and will not have any prior knowledge of the stage of development of the customers end product.

Dish Pharma further added that since it does not manufacture the innovators end product in contract research and manufacturing services (CRAMS) segment, it is Tesaro Inc., which has received the USFDA approval for cancer drug Zejula Capsules and not Dishman Pharma as mentioned in media reports.

Dishman Pharmaceuticals & Chemicals consolidated net profit rose 13.2% to Rs 50.68 crore on 7.6% decrease in net sales to Rs 356.47 crore in Q3 December 2016 over Q3 December 2015.

Dishman Pharmaceuticals & Chemicals acts as a full fledged CRAMS (contract research and manufacturing services) partner for global pharma innovators. It also makes phase transfer catalysts, Vitamin D, Vitamin D analogues, cholesterol, laolin related products, antiseptic and disinfectant formulations for pharmaceutical, cosmetic and related markets. The company also makes generic active pharmaceutical ingredients (API) and intermediates for the pharmaceutical industries.

Powered by Capital Market - Live News